While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is 5 feet, 7 ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is 5 feet, 7 inches tall, and weighs 270 pounds. He is treating his fluid retention with 100 ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

C urrently, Ozempic is only approved to treat type 2 diabetes. But in recent years, the semaglutide injection has become a ...

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.